secwatch.observer — SEC 8-K summary
======================================

Issuer:     Indivior Pharmaceuticals, Inc. (INDV)
CIK:        0001625297
Form:       8-K
Filed at:   2026-10-06T11:15:30+00:00
Accession:  0001104659-26-113883
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.35
Item codes: 8.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Indivior supplements merger proxy after Supernus stockholder suits; Cantor DCF values Indivior $24.20-$43.90
--------------------------------------------------------------------------------

- Supernus stockholders sent demand letters and filed two complaints in NY Supreme Court alleging the joint proxy/prospectus omitted material disclosure; Supernus denies merit but supplements.
- Cantor DCF reference range: Supernus $50.55-$59.50/share (9.5%-11.5% discount rate); Indivior $24.20-$43.90 dividend-adjusted (8.0%-10.0%).
- Merger: Artemis Merger Sub merges into Supernus, which survives as a wholly owned Indivior subsidiary; Indivior renamed Supernus, Inc. Special stockholder votes set for October 15, 2026.
- Indivior valued with ~$249M cash, ~$500M debt and a $1 billion Special Dividend; Supernus with ~$372M cash and $0 debt, using July 28, 2026 management data.
- Terminal growth assumptions range from -10.0% to +3.0% after Dec 31, 2040; fully diluted Indivior share count 124.0M-139.3M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1625297/000110465926113883/0001104659-26-113883-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1625297/000110465926113883/tm2627060d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-113883

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer